Your browser is no longer supported. Please, upgrade your browser.
NRx Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-7.95 Insider Own0.10% Shs Outstand51.74M Perf Week-20.75%
Market Cap203.32M Forward P/E- EPS next Y- Insider Trans-53.47% Shs Float23.88M Perf Month-37.10%
Income-319.20M PEG- EPS next Q- Inst Own4.10% Short Float9.37% Perf Quarter-67.15%
Sales- P/S- EPS this Y-596.10% Inst Trans12.30% Short Ratio0.74 Perf Half Y-82.29%
Book/sh0.17 P/B18.65 EPS next Y- ROA- Target Price- Perf Year-91.14%
Cash/sh0.61 P/C5.23 EPS next 5Y- ROE- 52W Range2.85 - 64.20 Perf YTD-33.68%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-95.06% Beta0.42
Dividend %- Quick Ratio1.20 Sales past 5Y- Gross Margin- 52W Low11.23% ATR0.42
Employees2 Current Ratio1.20 Sales Q/Q- Oper. Margin- RSI (14)29.62 Volatility12.48% 9.56%
OptionableYes Debt/Eq0.06 EPS Q/Q-761.00% Profit Margin- Rel Volume0.13 Prev Close3.17
ShortableYes LT Debt/Eq0.00 EarningsNov 16 BMO Payout- Avg Volume3.02M Price3.17
Recom- SMA20-27.67% SMA50-38.56% SMA200-77.04% Volume0 Change0.00%
Jan-26-22 06:51AM  
Jan-20-22 08:28PM  
Jan-18-22 06:48AM  
Jan-14-22 03:12PM  
Jan-12-22 05:48PM  
Jan-11-22 07:54AM  
Jan-07-22 05:50PM  
Jan-05-22 10:14AM  
Jan-03-22 07:16AM  
Dec-29-21 06:48AM  
Dec-19-21 06:38AM  
Dec-15-21 06:48AM  
Dec-14-21 06:48AM  
Dec-09-21 09:21AM  
Dec-06-21 09:07AM  
Nov-29-21 01:57PM  
Nov-26-21 10:06AM  
Nov-16-21 05:56AM  
Nov-12-21 11:46AM  
Nov-11-21 07:54AM  
Nov-09-21 05:25PM  
Nov-08-21 12:58PM  
Nov-05-21 05:45PM  
Nov-04-21 06:08PM  
Nov-02-21 11:04AM  
Oct-14-21 06:48AM  
Oct-12-21 06:48AM  
Sep-29-21 06:48AM  
Sep-27-21 07:04AM  
Sep-08-21 07:48AM  
Aug-30-21 08:06AM  
Aug-26-21 06:48AM  
Aug-25-21 09:43AM  
Aug-24-21 06:48AM  
Aug-23-21 09:33AM  
Aug-19-21 09:17AM  
Aug-18-21 11:53AM  
Aug-16-21 09:32PM  
Aug-11-21 04:20PM  
Aug-10-21 06:48AM  
Aug-09-21 01:13PM  
Aug-04-21 06:48AM  
Jul-27-21 11:34AM  
Jul-22-21 06:48AM  
Jul-19-21 06:48AM  
Jul-12-21 11:18AM  
Jul-06-21 09:20AM  
Jun-15-21 07:33AM  
Jun-09-21 02:50PM  
Jun-08-21 02:03PM  
Jun-07-21 01:45PM  
Jun-01-21 06:28AM  
May-27-21 06:48AM  
May-26-21 09:29AM  
NRX Pharmaceuticals, Inc., a clinical-stage small molecule pharmaceutical company, develops various therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company's pipeline includes medicinal candidates in Phase 2 and Phase 3 trials for COVID-19-related lung injury and acute respiratory distress. Its products include ZYESAMI, an investigational pre-commercial drug for COVID-19 related respiratory failure; and NRX-100/101, an investigational pre-commercial drug for treating bipolar depression in patients with acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Besthof RobertChief Comm. & Patient OfficerSep 15Sale11.7640,000470,40023,710Nov 02 04:04 PM
Daigneault AlessandraGeneral Counsel & SecretarySep 02Option Exercise3.0731,58496,96331,584Nov 02 04:05 PM
McMaster Herbert RaymondDirectorAug 26Option Exercise2.2218,30040,62618,300Nov 02 04:07 PM
Daigneault AlessandraGeneral Counsel & SecretaryAug 23Sale13.1133,715442,0040Nov 02 04:05 PM
Daigneault AlessandraGeneral Counsel & SecretaryAug 19Option Exercise3.0727,39584,10333,715Nov 02 04:05 PM
Besthof RobertChief Comm. & Patient OfficerAug 16Option Exercise0.2063,71012,74263,710Nov 02 04:04 PM